Bruno Tillier

Bruno Tillier
Bruno has been in charge of Synthelis since the very beginning, while it still was a Business Unit at Floralis, the technology transfer subsidiary at the University Joseph Fourier. When the company was independently launched in 2011, he became its CEO. Before, Bruno worked for five years as account manager at Floralis, and also at Cisbio Bioassays in the immunoassay department. Bruno has an M.Sc. in Medical Sciences from the South Alberta Cancer Research Institute (SACRI), Calgary, Canada. He also holds a Masters in Management from Reims Management School (RMS) and AgroParisTech (Masternova), where he focused on innovation in the Life Sciences.

Recent Posts

Cell-free systems to produce Virus-Like Particles !

Posted by Bruno Tillier on 17-Mar-2022 10:38:19

Virus-like particles (VLPs) are nanostructures consisting of assembled virus proteins that lack viral genetic material and, therefore, are non-infectious. Their interest relies in the possibility of using them to carry and deliver drugs, vaccines or imaging substances.

Read More

Topics: Cell-free technology, Proteins, Virus-Like-Particles

Mythbusting#1: Cell-free systems are only relevant for membrane proteins

Posted by Bruno Tillier on 02-Dec-2021 14:20:47

Cell-free protein synthesis (CFPS) methodology offers the possibility to produce proteins that would be difficult or even impossible to synthesize in cell-based systems. These so-called “difficult-to-express proteins” include membrane proteins, but also cytotoxic proteins (toxic cancer therapeutics, antimicrobial peptides/proteins and toxins), vaccines, antibodies and proteins containing non-standard amino acids [1]. Cell-free systems are, also, advantageous for the synthesis of proteins with biased coding sequences or with defined post-translational modifications, for the ones that require chaperones or specific chemical environments and even for the synthesis of virus-like particles and bacteriophages.

Read More

Topics: Cell-free technology, Proteins

Cell-free expressed OprF proteoliposomes as effective vaccine against Pseudomonas aeruginosa ?

Posted by Bruno Tillier on 29-Sep-2021 10:00:00

Synthelis' cell-free liposome-based expression system was applied in the development of an OprF vaccine against Pseudomonas aeruginosa. The complete OprF outer membrane protein of P. aeruginosa was used as the immunogen and was expressed in its native form in liposomes.

Read More

Topics: Proteins, Proteoliposomes

The S-protein receptor binding domain (RBD): potential uses for SARS-CoV-2 immunization and detection

Posted by Bruno Tillier on 06-Apr-2021 09:00:00

The S-protein receptor binding domain (RBD) of SARS-CoV-2 has been the subject of a thorough characterization and its importance in virus infection is well known. The potential uses of RBD of S-protein as a vaccine and as an antigen for the specific and sensitive detection of SARS-CoV-2 antibodies are herein reviewed.  

Read More

Topics: Proteins, SARS-CoV-2 S-protein RBD

Proteoliposomes - ideal model systems for membrane protein analysis

Posted by Bruno Tillier on 28-Jan-2021 12:27:14

Proteoliposomes – ideal model systems to study the structure and function of membrane proteins in semi-native environment by cryogenic electron microscopy

Read More

Topics: Proteins, Proteoliposomes

The nucleocapsid protein of SARS-CoV-2: potential target for a vaccine

Posted by Bruno Tillier on 17-Nov-2020 09:12:50

 

What is the N-Protein ?

The nucleocapsid protein (N protein) of SARS-CoV-2 is a structural protein synthesized by the virus, which plays a key role in the RNA packaging into the nucleocapsid. Its function is to mediate viral assembly through interaction with the viral genome and M protein, helping to increase viral RNA transcription and replication. Characterization studies have shown that N protein is very immunogenic and the antibodies against N protein present higher sensitivity and longer persistence than those against other structural proteins of SARS-CoV. These findings allow to consider N protein as a potential target for vaccine development against SARS-CoV-2.

Read More

Can we use cell-free biotechnology to fight COVID-19 ?

Posted by Bruno Tillier on 30-Jun-2020 11:02:05

With the COVID-19 pandemic still spreading across the globe, the fight is on to rapidly develop efficient solutions for diagnosis and treatment. In the past, cell-free protein expression has been used to produce antibodies against other strains of coronavirus. As such, could cell-free systems pose a viable option towards finding a solution against SARS-CoV-2 ?

Read More

Topics: Cell-free technology

Five reasons to label your proteins for NMR studies using cell-free systems.

Posted by Bruno Tillier on 18-Sep-2019 11:19:00

Isotope labelling has been used for over 40 years to facilitate the study of protein structure using nuclear magnetic resonance (NMR) spectroscopy. During that time, traditional expression systems such as in vivo protein synthesis were the preferred options for fabricating the labelled proteins. However, nearly a decade ago, it was discovered that cell-free protein expression offers an abundance of beneficial properties making it more adapted to the addition of isotopes than first thought. Here, we give you our top five reasons to use a cell-free system to label your proteins for your NMR study…

Read More

Topics: Cell-free technology, Proteins

Which extract is best for cell-free protein expression: wheat germ or E. coli?

Posted by Bruno Tillier on 05-Sep-2019 09:52:00

Cell-free protein expression offers a rapid, reliable technique for synthesis of proteins.  Successfully synthesizing large quantities of high-quality product requires finding the optimal protein expression conditions, such as the type of cellular extract used. Lysate choice for the cell- free reaction can affect expression feasibility, yield and cost. Which extract gives the best results? Here, we compare two of the most common: E. coli and wheat germ.

Read More

Topics: Cell-free technology, Biotech

Mythbusting #10 : “Cell-free systems are only relevant for protein synthesis"

Posted by Bruno Tillier on 16-Jul-2019 09:46:00

Cell-free systems are mainly used for in-vitro protein synthesis and can be considered as a powerful tool in genetic code reprogramming, involving the amber codon. In this use, the non-proteinogenic amino-acids are incorporated into proteins by charging them to suppressor-tRNAs molecules that reprogram the existing codons. However, cell-free systems are also used to engineer genetic circuits with applications for in-vitro biology or metabolic engineering.

Read More

Topics: Cell-free technology, Proteins, Biotech